Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Jul 6, 2007

Silence Therapeutics Could Earn $400M in siRNA Partnership with AstraZeneca

  • Silence Therapeutics entered into a collaboration with AstraZeneca primarily in the respiratory field that could be worth up to GBP 200 million, or approximately $400 million, plus royalties.

    The three-year R&D deal involves the discovery and development of siRNA molecules against up to five AstraZeneca targets. The firms will collaborate in the early phase of identification and optimization. AstraZeneca retains full responsibility for clinical development and commercialization. The agreement could be extended into other disease areas of interest to AstraZeneca.

    In addition, Silence Therapeutics will provide AstraZeneca with a license to its siRNA technology in return for an initial access fee of GBP 7.5 million, comprising GBP 2.5 million in cash plus an equity investment of GBP 5 million. AstraZeneca thus will hold 2.94% of the total voting rights of Silence Therapeutics.



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »